102
Participants
Start Date
April 1, 2024
Primary Completion Date
August 19, 2024
Study Completion Date
September 9, 2024
ALG-055009
Softgel Capsule
Placebo
Softgel Capsule
Aligos Clinical Study Site 7, New York
Aligos Clinical Study Site 13, Manassas
Aligos Clinical Study Site 8, Morehead City
Aligos Clinical Study Site 23, Athens
Aligos Clinical Study Site 32, Port Orange
Aligos Clinical Study Site 31, The Villages
Aligos Clinical Study Site 22, Ocoee
Aligos Clinical Study Site 30, Winter Park
Aligos Clinical Study Site 3, Viera
Aligos Clinical Study Site 25, Clearwater
Aligos Clinical Study Site 39, Fort Myers
Aligos Clinical Study Site 26, Bradenton
Aligos Clinical Study Site 38, Sarasota
Aligos Clinical Study Site 9, Nashville
Aligos Clinical Study Site 29, Louisville
Aligos Clinical Study Site 21, Columbus
Aligos Clinical Study Site 16, Westlake
Aligos Clinical Study Site 14, Chesterfield
Aligos Clinical Study Site 12, Topeka
Aligos Clinical Study Site 6, Metairie
Aligos Clinical Study Site 4, Marrero
Aligos Clinical Study Site 5, Houma
Aligos Clinical Study Site 24, Bastrop
Aligos Clinical Study Site 19, Austin
Aligos Clinical Study Site 40, Farmers Branch
Aligos Clinical Study Site 11, Waco
Aligos Clinical Study Site 33, Bellaire
Aligos Clinical Study Site 20, San Antonio
Aligos Clinical Study Site 28, Edinburg
Aligos Clinical Study Site 27, Brownsville
Aligos Clinical Study Site 18, Chandler
Aligos Clinical Study Site 15, Peoria
Aligos Clinical Study Site 17, Tucson
Aligos Clinical Study Site 35, Chula Vista
Aligos Clinical Study Site 37, Poway
Aligos Clinical Study Site 10, Rialto
Aligos Clinical Study Site 1, Lincoln
Aligos Clinical Study Site 34, Seattle
Aligos Clinical Study Site 2, Maitland
Aligos Clinical Study Site 36, East Greenwich
Lead Sponsor
Aligos Therapeutics
INDUSTRY